From the Nottingham University Hospitals and
Epidemiology and Public Health, Clinical Sciences Building, City Campus, Hucknall Road, Nottingham NG5 1PB, UK.
QJM. 2015 Nov;108(11):891-7. doi: 10.1093/qjmed/hcv052. Epub 2015 Feb 26.
Non-small cell lung cancer (NSCLC) in young adults is a rare but devastating illness with significant socioeconomic implications, and studies of this patient subgroup are limited.
This study employed the National Lung Cancer Audit to compare the clinical features and survival of young adults with NSCLC with the older age groups.
A retrospective cohort review using a validated national audit dataset.
Data were analysed for the period between 1 January 2004 and 31 December 2011. Young adults were defined as between 18 and 39 years, and all others were divided into decade age groups, up to the 80 years and above group. We performed logistic and Cox regression analyses to assess clinical outcomes.
Of a total of 1 46 422 patients, 651 (0.5%) were young adults, of whom a higher proportion had adenocarcinoma (48%) than in any other age group. Stage distribution of NSCLC was similar across the age groups and 71% of young patients had stage IIIb/IV. Performance status (PS) was 0-1 for 85%. Young adults were more likely to have surgery and chemotherapy compared with the older age groups and had better overall and post-operative survival. The proportion with adenocarcinoma, better PS and that receiving surgery or chemotherapy diminished progressively with advancing decade age groups.
In our cohort of young adults with NSCLC, the majority had good PS despite the same late-stage disease as older patients. They were more likely to have treatment and survive longer than older patients.
年轻成人非小细胞肺癌(NSCLC)是一种罕见但具有破坏性的疾病,具有重大的社会经济影响,对这一患者亚组的研究有限。
本研究利用国家肺癌审计数据,比较年轻成人 NSCLC 患者与老年患者的临床特征和生存情况。
使用经过验证的国家审计数据集进行回顾性队列研究。
分析了 2004 年 1 月 1 日至 2011 年 12 月 31 日期间的数据。年轻成人定义为 18 至 39 岁,其他所有人分为十年年龄组,直至 80 岁及以上组。我们进行了逻辑回归和 Cox 回归分析,以评估临床结果。
在总共 146422 名患者中,有 651 名(0.5%)为年轻成人,其中腺癌的比例(48%)高于任何其他年龄组。各年龄组的 NSCLC 分期分布相似,71%的年轻患者为 IIIb/IV 期。7%为 0-1。年轻成人比老年患者更有可能接受手术和化疗,并且整体和术后生存情况更好。腺癌、更好的 PS 以及接受手术或化疗的比例随着年龄的增长逐渐下降。
在我们的 NSCLC 年轻成人队列中,尽管与老年患者一样患有晚期疾病,但大多数患者 PS 良好。他们比老年患者更有可能接受治疗并存活更长时间。